Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Podcasts|December 21, 2021
Pharmacy Focus Podcast: Pharmacy Tech Talk- Episode 3
Judy Neville, program director of the college of pharmacy and pharmacy technician program at the University of Nebraska Medical Cancer, discusses what to look forward to for the AAPT conference in 2022.
Advertisement
In this month's episode, we talked with Judy Neville, program director of the college of pharmacy and pharmacy technician program at the University of Nebraska Medical Cancer, on what to look forward to for the American Association of Pharmacy Technicians Conference in 2022.
If you would like to share your Pharmacy Technician Tips, email agallagher@pharmacytimes.com!
Advertisement
Related to this article
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
What the 2025-2030 Dietary Guidelines Mean for Heart Health
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
5